ERN1 and neoplasm: Several IRE1 RNase inhibitors that block XBP1 splicing and RIDD; MKC3946, 3-methoxy-6-bromosalicylaldehyde, 4μ8C, STF-083010, and Toyocamycin, have shown promise in multiple myeloma models, where XBP1s is known to be important for tumour progression [80].